Uludağ, AhmetSılan, CoşkunAtik, SinemAkurut, CisemUludag, AysegulSılan, FatmaÖzdemir, Öztürk2025-01-272025-01-2720141945-02651945-0257https://doi.org/10.1089/gtmb.2013.0293https://hdl.handle.net/20.500.12428/24487Aim: Investigate the relationship between MDR1 C3435T polymorphism and colchicine response in Familial Mediterranean fever (FMF) patients. Materials and Methods: Patients (n=50) who received colchicine regularly, were willing to participate in the study, and attended control visits were included in the study. MDR1 C3435T genotype was defined by the real-time polymerase chain reaction method. Patients were divided into three groups. Patients, who recovered from episodes with standard colchicine treatment, and had no attack in the last 1 year were accepted as complete; patients whose episode number and intensity were decreased with the ongoing standard treatment as partial; and patients whose episodes were not decreased despite the standard treatment as nonresponders. Results:MDR1 C and T allele frequencies of FMF patients with colchicine responses of complete, partial, and nonresponders were C=0.75 and T=0.25; C=0.56 and T=0.44; and C=0.50 and T=0.50, respectively. When complete responding patients were compared with the partial responding patients, subjects with CT genotype had 6.18 times more increased risk than with CC genotype (OR=6.18; p=0.015). Poor response risk of subjects with the T allele was increased 2.45 times more when compared with the C allele (p=0.03). Conclusion:MDR1 gene C3435T polymorphism enacts an important role on colchicine response in FMF; good response to colchicine treatment was related to the C allele, whereas poor response was related to the T allele in FMF.eninfo:eu-repo/semantics/closedAccessMediated Multidrug-ResistanceGenetic PolymorphismsDrug TransportersExpressionProteinArticle182737610.1089/gtmb.2013.0293Q4WOS:0003313883000022-s2.0-8489381560924180297Q3